These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3382195)

  • 1. [Treatment of myelodysplastic syndromes (MDS) with oral administration of N4-palmitoyl-1-beta-D-arabinofuranosyl cytosine (PLAC)].
    Ohno R; Kimura K
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1205-8. PubMed ID: 3382195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) on hematological malignancies].
    Tatsumi N; Yamada K; Ohshima T; Nakamura T; Ohno R; Masaoka T; Kimura I; Kimura K
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2387-95. PubMed ID: 2260876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A phase II study of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PL-AC) in patients with acute leukemia and myelodysplastic syndromes. Cooperative Study Group for PL-AC].
    Kimura K
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2475-81. PubMed ID: 3619459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phase I study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate)].
    Fukuoka M; Miyazaki T; Yoshida Y; Hattori M; Niitani H; Nakamura T; Hirota Y; Ohta K; Tanaka M; Suzuoki Y
    Gan To Kagaku Ryoho; 1990 Nov; 17(11):2213-9. PubMed ID: 2241185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Quintas-Cardama A; Kantarjian H; O'Brien S; Jabbour E; Giles F; Ravandi F; Faderl S; Pierce S; Shan J; Verstovsek S; Cortes J
    Cancer; 2006 Oct; 107(7):1525-9. PubMed ID: 16955510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacokinetic study of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.
    Ohno R; Kimura K; Ota K; Miura Y; Hoshino A; Hattori K; Hirano M; Ito M; Maekawa T; Nakamura T
    Med Oncol Tumor Pharmacother; 1987; 4(2):67-73. PubMed ID: 3669779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Early phase II study of PL-AC [N4-palmitoyl-(1-beta-D-arabinofuranosyl) cytosine] on hematopoietic malignancies].
    Takubo T; Kubota Y; Tanaka T; Ueda T; Shibata H; Nakamura H; Masaoka T; Yoshitake J; Ishigami S
    Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):283-9. PubMed ID: 6576729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of leukemia and myelodysplastic syndromes with orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.
    Ohno R; Hirano M; Yamagata K; Ohara K; Shirakawa S; Hirota Y; Kobayashi M; Yoshikawa S; Mitomo Y; Ikeda Y
    Cancer Chemother Pharmacol; 1986; 17(2):161-4. PubMed ID: 3719896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
    Guan M; Chen SC; Ge CW
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase.
    Im T; Yamane T; Mugitani A; Hiyoshi M; Park K; Tatsumi N
    Int J Hematol; 1994 Oct; 60(3):215-23. PubMed ID: 7532031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
    Hiçsönmez G; Tuncer AM; Sayli T; Güler E; Cetin M; Ozbek N; Mufti GJ
    Hematol Pathol; 1995; 9(3-4):185-93. PubMed ID: 8655463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of treatment with 13-cis-retinoic acid and ara-C on the hematopoietic stem cells of patients with myelodysplastic syndromes].
    García Marco J; Miguel Sosa A; García Conde J; Miguel García A; Arbona C; Escrig V; Benet I; Navarro I; Ruiz A; Carbonell F
    Sangre (Barc); 1994 Aug; 39(4):241-4. PubMed ID: 7985051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
    Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
    J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topotecan in the treatment of hematologic malignancies.
    Beran M; Kantarjian H
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):26-31. PubMed ID: 9779879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Low-dose 4N-behenoyl-1-beta-D-arabinofuranosylcytosine (BHAC) in the treatment of atypical leukemia].
    Takahashi I; Nakada H; Hayashi N; Sekito N; Inagaki T; Aoyama S; Nonaka K; Ohmoto E; Kobayashi Y; Uchida K
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2780-5. PubMed ID: 3463249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vitamin K2 therapy for myelodysplastic syndrome].
    Abe Y; Muta K; Hirase N; Choi I; Matsushima T; Hara K; Taguchi F; Suematsu E; Shibata K; Uike N; Nishimura J; Nawata H
    Rinsho Ketsueki; 2002 Feb; 43(2):117-21. PubMed ID: 11925874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma].
    Suto T; Yoshida Y; Sakata Y; Ono T; Yoshida T; Yamada N; Chida N; Oohira H
    Gan To Kagaku Ryoho; 1998 Oct; 25(12):1933-8. PubMed ID: 9797816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.